Abvc Biopharma (ABVC) Cash & Equivalents (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Cash & Equivalents came in at $140324.0 in Q1 2026, down 7.81% YoY from $152206.0 in Q1 2025, and down 79.41% on a QoQ basis from $681480.0 in Q4 2025.
Abvc Biopharma (ABVC) Cash & Equivalents (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 15 years of Cash & Equivalents data on file, last reported at $140324.0 in Q1 2026.
- Quarterly Cash & Equivalents fell 7.81% year-over-year to $140324.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140324.0 (down 7.81% YoY) and the FY2025 annual result came in at $681480.0, up 174.37% from the prior year.
- Cash & Equivalents retreated to $140324.0 in Q1 2026, from $681480.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $2.0 million in Q3 2022 to a low of $60155.0 in Q4 2023.
- A 5-year average of $653198.9 and a median of $642899.0 in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents sank 95.68% — and 2024, when it surged 312.9%.
- Tracing ABVC's Cash & Equivalents over 5 years: stood at $1.4 million in 2022, then slumped by 95.68% to $60155.0 in 2023, then surged by 312.9% to $248382.0 in 2024, then soared by 174.37% to $681480.0 in 2025, then slumped by 79.41% to $140324.0 in 2026.
- The last three Cash & Equivalents figures came in at $140324.0 (Q1 2026), $681480.0 (Q4 2025), and $192068.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | 31,944.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31,944.00 |
| Mar 31, 2026 | 140,324.00 |
| Dec 31, 2025 | 681,480.00 |
| Sep 30, 2025 | 192,068.00 |
| Jun 30, 2025 | 388,251.00 |
| Mar 31, 2025 | 152,206.00 |
| Dec 31, 2024 | 248,382.00 |
| Sep 30, 2024 | 137,344.00 |
| Jun 30, 2024 | 124,296.00 |
| Mar 31, 2024 | 659,002.00 |
| Dec 31, 2023 | 60,155.00 |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 642,899.00 |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 1.39 Mn |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 688,633.00 |
| Mar 31, 2022 | 714,652.00 |
| Dec 31, 2021 | 6.57 Mn |
| Sep 30, 2021 | 3.72 Mn |